Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference
Fulgent Genetics (NASDAQ: FLGT) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company’s top executives, including CEO Ming Hsieh and CFO Paul Kim, will engage in a pre-recorded fireside chat, which will be accessible via their Investor Relations webpage for 90 days post-conference. Fulgent Genetics specializes in comprehensive testing solutions, notably in genetic testing and COVID-19 detection, emphasizing high accuracy, competitive turnaround times, and customizable testing options through their advanced technology platform.
- None.
- None.
TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis virtually participated in a pre-recorded fireside chat that will be published as part of the Piper Sandler 32nd Annual Healthcare Conference taking place December 1 to 3, 2020. Management will also be conducting virtual one-on-one investor meetings during the conference.
A webcast of the fireside chat will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com, and will be available for 90 days following the conference.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. The company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
FAQ
When will Fulgent Genetics participate in the Piper Sandler 32nd Annual Healthcare Conference?
Who will represent Fulgent Genetics at the healthcare conference?
How can I access the fireside chat by Fulgent Genetics?
What testing solutions does Fulgent Genetics offer?
What technology does Fulgent Genetics use for its testing services?
